Pancreatic Cancer Research

Clinical trialPhase 1Completed

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
19 July 2021
Ended
15 June 2023
Enrollment
25 participants
Sites
9
Primary outcomes
Frequency of TEAEs (Treatment-emergent adverse events); Number of participants with DTLs (dose-limiting toxicities); Number of subjects with 1 or more TEAEs leading to dose modifications; Number of subjects with grade ≥ 3 TEAEs; Percentage of subjects with grade ≥ 3 TEAEs
Sponsor type
Industry
Results posted
No
Last update
29 June 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.